For research use only. Not for therapeutic Use.
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2].
SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2].
SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2].
| Catalog Number | I045259 |
| CAS Number | 161511-45-1 |
| Synonyms | [(3S)-5-ethoxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-2,5-dioxopentyl] 2,6-dichlorobenzoate |
| Molecular Formula | C30H35Cl2N3O9 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H35Cl2N3O9/c1-5-42-24(37)14-22(23(36)16-43-29(40)25-20(31)12-9-13-21(25)32)34-27(38)18(4)33-28(39)26(17(2)3)35-30(41)44-15-19-10-7-6-8-11-19/h6-13,17-18,22,26H,5,14-16H2,1-4H3,(H,33,39)(H,34,38)(H,35,41)/t18-,22-,26-/m0/s1 |
| InChIKey | VMKPCENEHPIWJT-DOPYIHRPSA-N |
| SMILES | CCOC(=O)CC(C(=O)COC(=O)C1=C(C=CC=C1Cl)Cl)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)OCC2=CC=CC=C2 |
| Reference | [1]. Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11(1):13208. [2]. P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6. |
